62 results about "Maculopathy" patented technology

A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment to prevent or reduce the progression of proliferative diabetic retinopathy in said patient. Also disclosed is a non-surgical method of treating ocular conditions such as retinal ischemia, retinal inflammation, retinal edema tractional retinal detachment, tractional retinopathy, vitreous hemorrhage and tractional maculopathy by intravitreally administering to a patient suffering from one or more of these conditions with an effective amount of a serine proteinase enzyme to reduce or treat that particular ocular condition. Plasmin, microplasmin and miniplasmin are preferred serine proteinase enzymes and plasmin is the most preferred.

The invention discloses a traditional Chinese medicine for treating amblyopia eye diseases and relates to a preparation prepared from the traditional Chinese medicines as raw materials. The traditional Chinese medicine is prepared from semen cassiae, radix paeoniae alba, salvia miltiorrhiza, medlar, tuckahoe, dendrobe, kudzuvine root, tuber of dwarf lilyturf, tribulus terrestris, adenophora tetraphylla, yam, forsythia core, motherwort fruit, lophatherum gracile, antelope horn powder, glabrousleaf pittosporum seed and fructus psoraleae. The clinical use result of the traditional Chinese medicine shows that the prescription has the functions of enhancing the capability of supplying blood to caridiac muscle, promoting the blood circulation and improving the development process of eye parts of patients and promoting the repair of optic nerve and retina cells as well as the efficacies of nourishing the kidney, nourishing the liver and improving acuity of vision; the prescription can be used for treating amblyopia, hyperopia, yellow spot and other diseases caused by various reasons; and the traditional Chinese medicine has unique formula and curative effect, especially has remarkable effects for infants and juvenile patients and can ensure that the symptoms of the patients are eliminated and the visions of the patients are recovered.

The present inventors administered a peptide derived from VEGFR-2, which is known as one of the proteins involved in neovascularization, to model mice (A2/Kb transgenic mice) expressing human HLA-A*0201, and tested whether or not the peptide has vaccine effect. As a result, the present inventors successfully discovered that vaccination using this peptide as an antigen is effective for inhibition of choroid neovascularization, and thereby completed the present invention. More specifically, the present invention provides vaccines for treatment and/or prevention of diseases caused by choroid neovascularization (neovascular maculopathy), which contain a VEGFR-2-derived peptide as an active ingredient.

Apparatus for treating age-related macular degeneration, the apparatus comprising a light source which, in operation, serves to emit a therapeutic light beam presenting an emission wavelength lying in the range 1.2 μm to 1.3 μm, and preferably equal to 1.26 μm to 1.27 μm. The laser source preferably comprises an optical fiber Raman laser.

The present invention provides novel pharmaceutical agents and methods for treating or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy). The present invention provides pharmaceutical compositions and vaccines for treating and/or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy), comprising at least one type each of a peptide comprising an amino acid sequence derived from a VEGFR-1 protein and having an activity of inducing cytotoxic T cells, and a peptide comprising an amino acid sequence derived from a VEGFR-2 protein and having an activity of inducing cytotoxic T cells.

The invention firstly discloses an application of isoflavone in preparation of a drug for treating fundus maculopathy. The present invention finds for the first time that isoflavone can significantlyreduce the degree of fundus vascular permeability and has significant effect on fundus maculopathy. The invention not only provides the new use of isoflavone, but also provides the new drug for the treatment of fundus maculopathy, which has a good application prospect in the treatment of fundus maculopathy.

The invention provides a composition for preventing and treating young garlic shoot maculopathy. The composition for preventing and treating young garlic shoot maculopathy is a wettable powder agent which comprises active components, a dispersing agent, a moistening agent and a carrier, wherein the active components comprise indoleacetic acid, fulvic acid potassium and brassinolide. The preparation method comprises steps of uniformly mixing the components according to the ratio, and subsequently crushing the components to be 300-400 meshes. Before young garlic shoots are harvested, the composition is diluted with 500-1000 times of water and then is sprayed to leaves. The composition is remarkable in preventing and treating young garlic shoot maculopathy, simple in preparation process, low in cost, good in effect, high in biological security, and capable of increasing the yield of young garlic shoots.

The invention relates to a blue-light-resistant resin lens of 1.60 in refractivity. The blue-light-resistant resin lens comprises a resin substrate of 1.60 in refractivity, a hardened film layer is dipcoated on the resin substrate, and a first SiO2 film layer, a ZrO2 film layer, a second SiO2 film layer, a Ti2O3 film layer, an In2O3 film layer and a third SiO2 film layer are sequentially deposited on the surface of the hardened film layer. The blue-light-resistant resin lens can filter 40-50% of blue light of 400-500nm in wavelength and can effectively filter blue light radiation, pricking and soreness of eyes can be reduced, eye dryness and eye fatigue can be reduced, and cataract and maculopathy can be prevented.

The invention provides a dual-target fusion protein, which contains VEGF receptors and cell membrane fragments of PDGF beta receptors. Through the optimized combination of functional fragments, the present invention improves the binding ability of the fusion protein and the dual-target VEGF and PDGF β, can effectively inhibit the proliferation of new blood vessels, and achieve the treatment of neovascular proliferation diseases related to VEGF and PDGF β, such as tumor and wet age-related macular degeneration (AMD).

Apparatus and methods to improve the vision in a person with a macular disease, comprising the purposeful temporary creation of increased corneal optical aberrations. Strategies include corneal treatment patterns that are one or more of asymmetric, decentered or eccentric with respect to the visual axis, which would result in worsening vision in a normal eye but surprisingly become sight enhancing in a patient with the loss of foveal function due to macular disease.

The invention provides a method and reagent kit for detecting eye microorganisms, and an application of the reagent kit to diagnosis of age-related macular degeneration. The method for detecting eye microorganisms is a metagenome sequencing method and/or a real-time fluorescent quantitation PCR method. The invention further provides a medicine for killing or restraining microorganisms to treat theage-related macular degeneration, and a new method is provided for treatment of the age-related macular degeneration.

The invention discloses a medicine fusion specifically bound with human angiopoietin-2, and also discloses a preparation method of the medicine fusion and a method for treating senile maculopathy, tumors, inflammatory diseases and endometriosis by using the medicine fusion.

The invention discloses a gene medicine for preventing and treating neovascular eye diseases. The invention relates to the technical field of gene medicines, in particular to a recombinant vector which comprises a PEDF or PEDF functional fragment gene and a shRNA fragment targeting human VEGFA (vascular endothelial growth factor A). The invention also provides application of the recombinant vector in preparation of medicines for preventing or treating angiogenesis-related eye diseases. The PEDF overexpression and VEGFA interference adeno-associated virus involved in the invention can interfere with the expression level of the VEGFA in vascular endothelial cells, effectively down-regulate the protein level of the VEGFA, further inhibit the proliferation and migration activity of the vascular endothelial cells, and inhibit the angiogenesis ability of the vascular endothelial cells, so that a new target and approach for the treatment of wet maculopathy is provided.

The invention belongs to the fields of molecular biology, biochemistry and etiology, and discloses an APE1 inhibitor and application thereof in the preparation of drugs for the treatment of tumors and vascular poliferative diseases. The APE1 inhibitor has a structure shown in a following formula 1, by inhibiting the activity of the redox end of APE1, the formation process of tumors is inhibited from several aspects at the same time, compared with an existing APE1 inhibitor E3330, it is presented that the APE1 inhibitor is lower in cytotoxicity and has higher antiviral activity, antiangiogenic activity and anti-cell invasion activity and the like. The APE1 inhibitor has great application prospects on the treatment of various malignant tumors such as Kaposi's sarcoma, osteosarcoma, pancreatic cancers, bladder cancers, ovarian cancers and other cancers, and other abnormal vascular proliferative diseases such as age-related macular degeneration. The formula 1 is shown in the description.

The invention relates to a medical health care product for resisting antioxidation, delaying aging and preventing age-related macular degeneration, and a preparation method thereof. The traditional Chinese medicine and health care product composition comprises the following components by weight: 15-25 parts of astaxanthin and 6-14 parts of lutein. The composition is supplemented with auxiliaries acceptable in preparation process and can be prepared into hard capsule, soft capsule, oral liquid and other oral preparation. The composition uses astaxanthin and lutein as raw materials, aims at the physical features and diet culture of Chinese, is subjected to scientific quantitative ratio to maximizes the synergic effects of resisting antioxidation, delaying aging and preventing age-related macular degeneration; and the action characteristics of the two varieties complement each other, so that the composition has the comprehensive and obvious effects of resisting antioxidation, delaying aging and preventing age-related macular degeneration.

The invention belongs to the technical field of light feeding instruments, and discloses a light feeding instrument with adjustable treatment intensity, which comprises a bottom support assembly, a red light generation assembly, a lens cone assembly and a control unit. The bottom supporting assembly is used for forming an installation foundation of the treatment-intensity-adjustable nursing light instrument, the bottom supporting assembly comprises a base, a hollow supporting column and a supporting rod, the base is horizontally arranged, the hollow supporting column is vertically and fixedly installed on the upper portion of the base, and the supporting rod is installed in the upper end of the hollow supporting column through an adjusting bolt; the red light generating assembly is used for generating red light. According to the light feeding instrument with the adjustable treatment intensity, the intensity of the generated treatment red light is adjustable, the requirement for myopia treatment of myopia patients with different myopia degrees can be met, the treatment effect is good, and the use limitation is effectively eliminated; more importantly, the risk of fundus lesion, maculopathy and other potential side effects caused by overhigh red light intensity or long-time use can be reduced.

The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a retinopathy (e.g., diabetic retinopathy) and/or maculopathy (e.g., age-related macular degeneration) in a subject in need thereof.